These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31714637)

  • 1. Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.
    Adami G; Jaleel A; Curtis JR; Delzell E; Chen R; Yun H; Daigle S; Arora T; Danila MI; Wright NC; Cadarette SM; Mudano A; Foster J; Saag KG
    J Bone Miner Res; 2020 Mar; 35(3):478-487. PubMed ID: 31714637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
    Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
    BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with weekly alendronate therapy among postmenopausal women.
    Lo JC; Pressman AR; Omar MA; Ettinger B
    Osteoporos Int; 2006; 17(6):922-8. PubMed ID: 16609824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
    Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
    Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
    Kim M; Lin TC; Arora T; Zhao H; Balasubramanian A; Stad RK; O'Kelly J; Spangler L; Bradbury BD; Curtis JR
    J Bone Miner Res; 2023 Jun; 38(6):829-840. PubMed ID: 37088886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
    Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
    Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
    Hayes KN; Ban JK; Athanasiadis G; Burden AM; Cadarette SM
    Osteoporos Int; 2019 Nov; 30(11):2311-2319. PubMed ID: 31317249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular Side Effects of Bisphosphonates: A Review of Literature.
    Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
    J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration.
    Miller PD; McCarthy EF
    Semin Arthritis Rheum; 2015 Apr; 44(5):477-482. PubMed ID: 25312241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
    Anastasilakis AD; Goulis DG; Kita M; Avramidis A
    Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
    Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
    Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
    Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.